Privigen (human immune globulin intravenous 10%) / CSL Behring - LARVOL DELTA

Chronic persistent norovirus infection in renal transplant recipient and combination therapy with nitazoxanide and enteral immunoglobulin (TTS 2026) - "The patient was commenced on combination therapy with oral immunoglobulin (Privigen ® 10%, 2 grams every 6 hours for eight doses) and oral nitazoxanide 500 mg twice daily for 14 days for chronic norovirus enteritis. This case demonstrates that combination therapy with oral immunoglobulin and nitazoxanide was associated with symptom benefit and nutritional improvement in chronic norovirus infection despite persistent asymptomatic viral shedding. This is a potential therapeutic option in immunocompromised patients pending the development of directly acting antivirals. Further studies are required to define its role in management."

Clinical • Combination therapy • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Gastrointestinal Disorder • Infectious Disease • Nephrology • Transplant Rejection • Transplantation

Hyperacute Liver Injury After Proline-Stabilized IVIG: A Rare Non-Acetaminophen DILI Successfully Treated With N-Acetylcysteine (ACG 2026) - "We present a unique case of hyperacute Privigen-induced hepatitis in a young female with Myasthenia Gravis (MG), which rapidly resolved following an NAC infusion. Case Description/ A 20-year-old female with a history of generalized Myasthenia Gravis (on maintenance prednisone, pyridostigmine, and mycophenolate mofitil) was admitted for a myasthenic crisis presenting with bulbar symptoms and bilateral lower extremity weakness...Although the mechanism is unclear, IV Nâacetylcysteine may accelerate recovery in nonâacetaminophen IVIG hepatotoxicity. Early recognition can avoid unnecessary liver biopsy and supports a safe, effective management approach. Figure: Figure: Trending liver enzymes and bilirubin"

Autoimmune Hepatitis • CNS Disorders • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Failure • Myasthenia Gravis

Extended Investigation Into the Viscosity of Commercial IG Preparations (ISTH 2026) - "Our extended datanow includes product viscosity at normal body temperature (37° C.) Methods Experiments were performed using: ALYGLO® (immune globulin intravenous, human-stwk 10% liquid), GC Biopharma; OCTAGAM®10% [immune globulin intravenous (human) 10% liquid], Octapharma; GAMUNEX®-C [immune globulin injection (human), 10% caprylate/chromatography purified], Grifols Therapeutics LLC; PRIVIGEN® [immune globulin intravenous (human), 10% liquid], CSLBehring LLC; and GAMMAGARD LIQUID® [immune globulin infusion (human) 10%], Takeda Pharmaceuticals...Results The results at 25 °C were as follows: ALYGLO: 2.587 cP; OCTAGAM: 2.646 cP; GAMUNEX-C: 2.598 cP; PRIVIGEN: 2.598 cP; GAMMAPLEX: 2.598 cP...The consistency between the first and second analyses supports the robustness of these observations and warrants further investigation to identify potential differences in the viscosities of commercially available IVIG products, which may have..."

Cardiovascular • Nephrology • Renal Disease

80202135CDP3001: Efficacy and Safety Study of Nipocalimab for Adults with CIDP (clinicaltrialsregister.eu) - P1/2 | N=85 | Recruiting | Sponsor: Janssen Cilag International | N=65 ➔ 85

Enrollment change • Pain

ASSESSMENT OF CLINICALLY RELEVANT AUTOANTIBODIES IN IVIG PRODUCTS BEFORE AND AFTER COVID-19 PANDEMIC (AUTO 2026) - "Despite the eightfold increase in the total concentration of autoantibodies (ANA Hep-2 titer) in IVIG products, most specific, potentially pathogenic autoantibodies remain below the reference limits, which requires further investigation and monitoring of the clinical significance of the total increase."

Clinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Investigation Into the Viscosity of Commercial IG Preparations (CIS 2026) - "Experiments were performed using: ALYGLO (immune globulin intravenous, human-stwk 10% liquid), GC Biopharma; OCTAGAM10% (immune globulin intravenous [human] 10% liquid), Octapharma; GAMUNEX-C (immune globulin injection [human], 10% caprylate/chromatography purified), Grifols Therapeutics LLC; PRIVIGEN (immune globulin intravenous [human], 10% liquid), CSL Behring LLC; and GAMMAGARD LIQUID (immune globulin infusion [human] 10%), Takeda Pharmaceuticals...The results at 25°C were as follows: ALYGLO: 2.587 cP; OCTAGAM: 2.646 cP; GAMUNEX-C: 2.598 cP; PRIVIGEN: 2.598 cP; GAMMAPLEX: 2.598 cP...The consistency between the first and second analyses supports the robustness of these observations and warrants further investigation to identify potential differences in the viscosities of commercially available IVIG products, which may have implications for product selection in at-risk patients. Tabular data are included as downloadable supplement files."

Cardiovascular • Nephrology • Renal Disease

80202135CDP3001: Efficacy and Safety Study of Nipocalimab for Adults with CIDP (clinicaltrialsregister.eu) - P1/2 | N=60 | Recruiting | Sponsor: Janssen Cilag International | N=45 ➔ 60

Enrollment change • Pain

EMPIRICAL TIME-SERIES ANALYSES IN THE PAST THREE DECADES 1991-2023 FOR IMMUNE THROMBOCYTOPENIA MEDICATIONS IN THE US MEDICAID PROGRAMS (ISPOR 2026) - "Study medications target platelet count restoration and immune system modulation, including thrombopoietin receptor agonists (TPO-RA), such as Nplate (Romiplostim) and Promacta (Eltrombopag), and IV immunoglobulin (e.g., Gammagard) or anti-D immunoglobulin, Rituximab (an anti-CD20 monoclonal antibody), and newer Tyrosine kinase inhibitors...Comparative market-share analyses were also conducted within and across therapeutic classes Utilization trends revealed Rituxan dominated until 2020, after which biosimilars (Ruxience, Truxima) gained traction, with Ruxience leading. In the IVIG category, Gammagard consistently held the highest utilization, peaking in 2022, followed by Rhophylac and Privigen...Pricing data highlighted Promacta as the most expensive TPO-RA, while Panzyga led IVIG pricing by 2019... Analysis highlights evolving patterns in the utilization, reimbursement, and pricing of ITP therapies within Medicaid programs, shaped by factors such as the introduction of..."

Medicaid • Reimbursement • US reimbursement • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

IVIORDEX: IgIV Plus Prednisone vs High-dose Dexamethasone for ITP (clinicaltrials.gov) - P3 | N=272 | Recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris | Active, not recruiting ➔ Recruiting

Enrollment open • Congestive Heart Failure • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

IVIORDEX: IgIV Plus Prednisone vs High-dose Dexamethasone for ITP (clinicaltrials.gov) - P3 | N=272 | Active, not recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris | Recruiting ➔ Active, not recruiting

Enrollment closed • Congestive Heart Failure • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Effects of Various Immunoglobulin Products on Serum (1-3)-β-D-glucan Levels. (PubMed, Transpl Infect Dis) - "Different immunoglobulin products have different effects on serum β-D-glucan levels after IgRT."

Journal • Infectious Disease • Transplantation

Open-label Trial of IVIG in Children With PANS (clinicaltrials.gov) - P2 | N=17 | Completed | Sponsor: Göteborg University | Recruiting ➔ Completed | N=10 ➔ 17 | Trial completion date: Dec 2026 ➔ Oct 2025 | Trial primary completion date: Dec 2026 ➔ Oct 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Pediatrics • Psychiatry

The CoVIg study: Randomized Open Label Trial Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIg, Privigen) as Add-on to SoC Versus SoC Alone for Coronavirus Disease 2019 (COVID-19) in Patients with Severely Impaired B-cell Function (clinicaltrialsregister.eu) - P1/2 | N=92 | Not yet recruiting | Sponsor: Region Vaesterbotten, Umea University

New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

TINISS: Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies (clinicaltrials.gov) - P3 | N=24 | Not yet recruiting | Sponsor: University Hospital, Strasbourg, France

New P3 trial • Pain • Sjogren's Syndrome

TINISS: Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies (clinicaltrials.gov) - P3 | N=24 | Completed | Sponsor: University Hospital, Strasbourg, France | Recruiting ➔ Completed | Trial completion date: Jul 2026 ➔ Apr 2025 | Trial primary completion date: Dec 2025 ➔ Apr 2025

Trial completion • Trial completion date • Trial primary completion date • Immunology • Pain • Sjogren's Syndrome

TINISS: Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies (clinicaltrials.gov) - P3 | N=24 | Recruiting | Sponsor: University Hospital, Strasbourg, France | Trial completion date: Dec 2022 ➔ Jul 2026 | Trial primary completion date: Dec 2022 ➔ Dec 2025

Trial completion date • Trial primary completion date • Pain • Sjogren's Syndrome

TINISS: Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies (clinicaltrials.gov) - P3 | N=24 | Recruiting | Sponsor: University Hospital, Strasbourg, France | Trial completion date: Jul 2021 ➔ Dec 2022 | Trial primary completion date: Jun 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date • Pain • Sjogren's Syndrome

TINISS: Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies (clinicaltrials.gov) - P3 | N=24 | Recruiting | Sponsor: University Hospital, Strasbourg, France | Trial completion date: Dec 2020 ➔ Jul 2021 | Trial primary completion date: Dec 2020 ➔ Jun 2021

Trial completion date • Trial primary completion date • Pain • Sjogren's Syndrome

TINISS: Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies (clinicaltrials.gov) - P3 | N=24 | Recruiting | Sponsor: University Hospital, Strasbourg, France | Not yet recruiting ➔ Recruiting | Initiation date: Jan 2019 ➔ Jun 2019

Enrollment open • Trial initiation date • Pain • Sjogren's Syndrome

A case series on cutaneous reactions to ivig (ASH 2025) - "The rash lacked mucosal involvement and was disseminatedbeyond sun-exposed areas, first appeared two months after commencing IVIg in November 2022.Despite ongoing systemic corticosteroids and withdrawal of other, potential culprit drugs includingvoriconazole and benralizumab, the rash persisted with cyclical flares over 15 months with somecorticosteroid responsiveness...Rechallenge with IVIg (Octogam) later in 2025 resulted in rapidrecurrence of the exanthema, suggesting a likely causative role.Case 2 depicts an 88-year-old male with chronic lymphocytic leukaemia (CLL), receiving zanubrutinibsince October 2023, with significant hypogammaglobulinaemia for which he was initiated on IVIg. Afterthree uneventful infusions of IVIg (Privigen AU) in 2023, he developed a severe, desquamatingerythrodermic rash following the fourth dose...Over a year later, the patient was re-challenged with analternative IVIg product (Octagam)...Nonetheless, further research is crucial touncover..."

Clinical • Asthma • Atopic Dermatitis • Chronic Lymphocytic Leukemia • Dermatology • Dermatopathology • Hematological Malignancies • Immunology • Leukemia • Respiratory Diseases • Steven-Johnson Syndrome

IVIG vs SCIG in CIDP (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Rutgers, The State University of New Jersey | Active, not recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Enrollment open • Trial completion date • Trial primary completion date • Pain

Intravenous Immunoglobulin and Prednisolone for RPL After ART. (clinicaltrials.gov) - P2 | N=80 | Completed | Sponsor: Aalborg University Hospital | Recruiting ➔ Completed

Trial completion

Unmasking the ABO Antibody Ingredient List in IVIg Preparations (WTC 2025) - "We used a LuminexTM single-antigen bead assay to measure ABO-Ab to A and B subtypes glycans to detect the ABO-Ab in commercially available IVIg products.* Thirteen IVIg lot numbers from six IVIg preparations (Privigen, Cuvirtru, Cutaquig, Hizentra, Octagram, and Gammagard Liquid) were evaluated using LuminexTM beads coupled to individual subtype ABO-A and -B glycans (subtypes I through VI)... It is valuable to know the level of ABO-Ab in IVIg for many reasons. In many clinical scenarios beyond transplantation, these ABO-Ab may cause IVIg-related red cell hemolysis. In the setting of ABO-incompatible transplantation, the presence of passively acquired ABO-Ab may interfere with the measurement of patient ABO-Ab levels pre- and post-transplant."

Hematological Disorders

IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus (clinicaltrials.gov) - P2 | N=20 | Active, not recruiting | Sponsor: The University of Hong Kong | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date

Investigation Into the Viscosity of Commercial IVIG Preparations (ISTH 2025) - "Methods Experiments were performed using: ALYGLO™ (immune globulin intravenous, human-stwk 10% liquid), GC Biopharma; OCTAGAM® 10% [immune globulin intravenous (human) 10% liquid], Octapharma; GAMUNEX®-C [immune globulin injection (human), 10% caprylate/chromatography purified], Grifols Therapeutics LLC; PRIVIGEN® [immune globulin intravenous (human), 10% liquid], CSL Behring LLC, and GAMMAGARD LIQUID® [immune globulin infusion (human) 10%], Takeda Pharmaceuticals...Results The results at 25°C were as follows: ALYGLO: 2.506 cP; OCTAGAM: 3.484 cP; GAMUNEX-C: 2.535 cP; PRIVIGEN: 2.698 cP; GAMMAGARD LIQUID: 2.575 cP. For reference, viscosity of human plasma at 25°C generally ranges from 1.5-1.72 cP. Table or Figure Upload"

Cardiovascular • Nephrology • Renal Disease